GlassScriptPhysician profile
Nicole Olivas
NPI 1366030546
$10,089.82
in general payments reported to CMS, 2019-2025
25 companies · $23.62 in 2025
The $23.62 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $5,110 · 2023: $4,827 · 2024: $130 · 2025: $23.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,980.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,570.65 | 2022-2023 | Spravato, Invega, Invega Sustenna |
| Abbvie INC. | $1,185.42 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $1,107.74 | 2022-2023 | Austedo, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,015.96 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $1,000.64 | 2022-2023 | Ingrezza |
| Vanda Pharmaceuticals INC. | $707.66 | 2022-2023 | Hetlioz, Fanapt |
| Otsuka America Pharmaceutical, INC. | $593.31 | 2022-2023 | Rexulti, Nuedexta, Abilify Asimtufii |
| Alkermes, INC. | $539.65 | 2022-2023 | Aristada, Lybalvi |
| Lundbeck LLC | $474.05 | 2022-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $358.68 | 2022-2023 | Trintellix |
| Axsome Therapeutics, INC. | $357.96 | 2022-2023 | Auvelity |
| Sunovion Pharmaceuticals INC. | $319.53 | 2022 | |
| Noven Therapeutics, LLC | $144.80 | 2022-2023 | Secuado, Xelstrym |
| Corium, LLC | $141.32 | 2023 | Azstarys |
| Indivior INC. | $111.96 | 2022-2023 | Perseris, Sublocade |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $98.18 | 2023 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $68.77 | 2023-2024 | Qelbree, Qelbree |
| Avanir Pharmaceuticals, INC. | $57.37 | 2022 | |
| Merck Sharp & Dohme LLC | $49.68 | 2022-2023 | Belsomra |
| Livanova USA, INC. | $45.81 | 2022 | |
| Sumitomo Pharma America, INC. | $39.70 | 2023 | Latuda |
| Idorsia Pharmaceuticals US INC | $36.83 | 2023 | Quviviq |
| Novo Nordisk INC | $23.83 | 2023 | Wegovy |
| Spr Therapeutics, INC | $23.62 | 2025 | Sprint Pns System |
| Ardelyx, INC. | $16.70 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Olivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.